OBSOLETE: Atypical teratoid/rhabdoid tumor

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:251891
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Atypical teratoid/rhabdoid tumor (AT/RT) is a highly aggressive and rare malignant tumor of the central nervous system (CNS) that predominantly affects very young children, most commonly those under three years of age. This Orphanet entry (251891) is marked as OBSOLETE, meaning it has been retired or reclassified within the Orphanet nomenclature, and information may now be catalogued under an updated or alternative entry. AT/RT is characterized by the presence of rhabdoid cells and typically arises in the brain (particularly the posterior fossa/cerebellum) or, less commonly, in the spinal cord. The tumor is strongly associated with biallelic inactivation or loss of the SMARCB1 (INI1/hSNF5) gene on chromosome 22q11.2, and rarely with SMARCA4 mutations. These genes encode components of the SWI/SNF chromatin-remodeling complex, and their loss drives uncontrolled cell growth. Clinical features depend on tumor location but commonly include increased intracranial pressure leading to headaches, vomiting, lethargy, and increasing head circumference in infants. Neurological deficits such as cranial nerve palsies, ataxia, and developmental regression may also be present. Because of its rapid growth, symptoms often progress quickly. AT/RT accounts for approximately 1–2% of all pediatric CNS tumors but represents a significant proportion of CNS tumors in children under one year of age. Treatment typically involves a multimodal approach including maximal safe surgical resection, intensive chemotherapy regimens, and in some cases radiation therapy, although the use of radiation is limited in very young children due to neurotoxicity concerns. Despite aggressive treatment, prognosis remains poor, with historically low survival rates, though recent intensified treatment protocols have improved outcomes for some patients. Ongoing clinical trials are exploring targeted therapies and novel agents aimed at the molecular pathways disrupted by SMARCB1 loss.

Also known as:

Inheritance

Variable

Can be inherited in different ways depending on the underlying gene

Age of Onset

Infantile

Begins in infancy, roughly 1 month to 2 years old

Orphanet ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for OBSOLETE: Atypical teratoid/rhabdoid tumor.

View clinical trials →

No actively recruiting trials found for OBSOLETE: Atypical teratoid/rhabdoid tumor at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the OBSOLETE: Atypical teratoid/rhabdoid tumor community →

No specialists are currently listed for OBSOLETE: Atypical teratoid/rhabdoid tumor.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to OBSOLETE: Atypical teratoid/rhabdoid tumor.

Search all travel grants →NORD Financial Assistance ↗

Community

Open OBSOLETE: Atypical teratoid/rhabdoid tumorForum →

No community posts yet. Be the first to share your experience with OBSOLETE: Atypical teratoid/rhabdoid tumor.

Start the conversation →

Latest news about OBSOLETE: Atypical teratoid/rhabdoid tumor

No recent news articles for OBSOLETE: Atypical teratoid/rhabdoid tumor.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about OBSOLETE: Atypical teratoid/rhabdoid tumor

What is OBSOLETE: Atypical teratoid/rhabdoid tumor?

Atypical teratoid/rhabdoid tumor (AT/RT) is a highly aggressive and rare malignant tumor of the central nervous system (CNS) that predominantly affects very young children, most commonly those under three years of age. This Orphanet entry (251891) is marked as OBSOLETE, meaning it has been retired or reclassified within the Orphanet nomenclature, and information may now be catalogued under an updated or alternative entry. AT/RT is characterized by the presence of rhabdoid cells and typically arises in the brain (particularly the posterior fossa/cerebellum) or, less commonly, in the spinal cord

At what age does OBSOLETE: Atypical teratoid/rhabdoid tumor typically begin?

Typical onset of OBSOLETE: Atypical teratoid/rhabdoid tumor is infantile. Age of onset can vary across affected individuals.